Spartalizumab (INN; development code PDR001) is a monoclonal antibody and checkpoint inhibitor that is being investigated for melanoma. This drug is being developed by Novartis. As of 2018, spartalizumab is undergoing Phase III trials.
Property | Value |
---|---|
dbo:abstract |
|
dbo:casNumber |
|
dbo:fdaUniiCode |
|
dbo:kegg |
|
dbo:wikiPageID |
|
dbo:wikiPageLength |
|
dbo:wikiPageRevisionID |
|
dbo:wikiPageWikiLink | |
dbp:atcPrefix |
|
dbp:casNumber |
|
dbp:kegg |
|
dbp:mabType |
|
dbp:source |
|
dbp:synonyms |
|
dbp:target | |
dbp:type |
|
dbp:unii |
|
dbp:wikiPageUsesTemplate | |
dcterms:subject | |
rdf:type | |
rdfs:comment |
|
rdfs:label |
|
owl:sameAs | |
prov:wasDerivedFrom | |
foaf:isPrimaryTopicOf | |
is dbo:wikiPageWikiLink of | |
is foaf:primaryTopic of |